There are some catalysts that could push the stock price to $10.

Actinium Pharmaceuticals (ATNM) shares pumped to $9.17 on Feb.3 and have been trading above $9 per share in the last few days. The stock price is showing resistance, so could the stock jump past $10 per share?

Lately, there has been no news for Actinium. However, there are a few notable developments that could become the possible catalyst in driving the stock in the coming days.

The most recent one is the research partnership with Astellas Pharma. The collaboration is based on the development of novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform.

What’s Happening?

Earlier this year, Actinium Pharmaceuticals (ATNM) announced its deal with Astellas Pharma. Both the pharmaceutical firms will be working on novel targeted radiotherapies. The company will provide its AWE Platform technology to develop specific selected Astellas targeting agents labeled with the potent alpha-emitting radioisotope Actinium-225 (Ac-225). 

The R&D teams from both firms will join forces. Astellas being a leader at the forefront of healthcare innovation would help Actinium in this project. The Chief Scientific and Technology Officer at Actinium, Dr. Dale Ludwig stated that their enhanced laboratory ecosystem and the expertise of their R&D team would strategically help them with their R&D strategy—with Astellas. The basic object would be to complementActinium’s Iomab-B and Actimab-A clinical programs.

Currently, Actinium is working on its lead product candidate, I-131 apamistamab (Iomab-B). I-131 is under the Phase-3 study of Iomab-B for the treatment of Acute Myeloid Leukemia. The company has already completed 75% of enrollment in the final phase. While the company has also reported positive safety data at several annual meetings including ASH, ASCO, SOHO, and TCT.

Actinium has plans to study I-131 apamistamabin a Phase 1 study with a CD19 CAR T-cell Therapy and Phase 1/2 anti-HIV stem cell gene therapy with UC Davis—as a targeted condition agent.

Moreover, the company is working on several other top-end projects including a multi-target pipeline of clinical-stage ARCs. These studies are also being conducted to tackle other forms of Leukemia.

Conclusion

Actinium Pharmaceuticals (ATNM) is moving forward towards its ongoing projects. The partnership with Astellas would help the company to have broader access to the market. Moreover, perform better research to ensure that they achieve what they are looking for.

In Dec, Zacks projected ATNM to post earnings of -$0.59 per share in the upcoming quarter, which shows a 50.83% increase Year-over-Year. The signs are positive and ATNM could rally past $10 per share.